-
-
-
-
-
-
-
Amgen (AMGN) Announces Positive Topline Phase 3 Results For Bemarituzumab In Fibroblast Growth Factor Receptor 2B (Fgfr2B) Positive First-line Gastric Cancer
-
-
-
-
-
-
-
Sangamo Therapeutics (SGMO) Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
-
-
-
-
-
-
-
Incyte (INCY): Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
-
-
-
-
-
-
-
Immix Biopharma (IMMX) Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
-
-
-
-
-
-
-
Summit Therapeutics (SMMT): Ivonescimab Plus Chemo Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients with EGFR-Mutant NSCLC
-
-
-
-
-
-
-
Pfizer (PFE) Prostate Cancer Drug Fails To Get FDA Panel Backing - Bloomberg
-
-
-
-
-
-
-
Tourmaline Bio (TRML) Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and CKD
-
5,842 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving Hot FDA News reports.